Oppenheimer analyst Hartaj Singh remains bullish on Sarepta after the company presented long-term data on the potential benefits of Exondys 51 on cardiac and pulmonary function. The analyst notes that while clinical trial data for patients on drug for less than one year is "not very compelling," long-term data on cardiac and pulmonary complications demonstrates the drug slowing progression. It is this data that has created a positive buzz among the Duchenne Muscular Dystrophy community and is key in the European application, he argues. Singh reiterates an Outperform rating and $76 price target on the shares.